Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
| 06-2025 | 06-2024 | 06-2023 | 06-2022 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,628 | 3,094 | 11,247 | 14,549 | 19,986 |
| Receivables | 73 | N/A | N/A | N/A | N/A |
| TOTAL | $11,963 | $3,508 | $11,670 | $15,579 | $21,654 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 183 | 565 | 0 | 0 | 0 |
| TOTAL | $183 | $565 | $N/A | $N/A | $N/A |
| Total Assets | $12,146 | $4,073 | $11,670 | $15,579 | $21,654 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 224 | 156 | 535 | 381 | 110 |
| Accrued Expenses | 264 | 104 | 534 | 132 | 132 |
| TOTAL | $488 | $261 | $1,069 | $513 | $242 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $488 | $261 | $1,069 | $513 | $242 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,085 | 25,933 | 25,633 | 23,369 | N/A |
| Common Shares | 41 | 26 | 26 | 23 | 23 |
| Retained earnings | -73,889 | -65,404 | -57,202 | -45,470 | -38,644 |
| TOTAL | $11,658 | $3,813 | $10,601 | $15,067 | $21,412 |
| Total Liabilities And Equity | $12,146 | $4,073 | $11,670 | $15,579 | $21,654 |